New Data on AlloSure Confirms Its Clinical Utility in Repeat Kidney Transplant Recipients
AlloSure is the first donor-derived cell-free DNA test to assess allograft health and is broadly available to transplant patients. Previous publications demonstrating the clinical value of AlloSure were based on first-time or single kidney transplant recipients (SKTR); the current study is the first study to include repeat kidney transplant recipients (RKTR).
“A significant percentage of patients require repeat kidney transplants and are at a higher risk for rejection,” said
Key highlights from the study:
- In patients without evidence of rejection, the median readouts of AlloSure were significantly lower than threshold levels for rejection in both SKTR and RKTR
- In patients with active rejection, AlloSure levels were similarly elevated in SKTR and RKTR patients alike
“CareDx believes in personalizing healthcare for all kidney transplant patients including those at high risk. This peer-reviewed publication supports the expanded clinical utility of AlloSure to include repeat kidney transplant recipients,” said
Full Reference: Repeat kidney transplant recipients with active rejection have elevated donor‐derived cell‐free DNA. Mannon RB, et al.
For more information, please visit: www.CareDx.com.
Integrated Corporate Relations, Inc.
Source: CareDx, Inc.